Clear Cell Variant of a Follicular Thyroid Tumor With Uncertain Malignant Potential: A Case Report

2018 ◽  
Vol 27 (3) ◽  
pp. 290-293 ◽  
Author(s):  
C. Christofer Juhlin ◽  
Robert Bränström ◽  
Ivan Shabo ◽  
Anders Höög

Follicular neoplasms of the thyroid gland are most often characterized by follicular-patterned thyrocytes with a neutrally stained cytoplasm, while a minority of cases present with oncocytic differentiation (Hürthle cell tumors). Exceedingly rare variants with a clear cell phenotype have also been reported, both as clear cell follicular thyroid adenomas (ccFTAs) and clear cell follicular carcinomas (ccFTCs). We present a patient with a 30-mm lesion in the thyroid isthmus in which the preoperative cytology proposed a follicular tumor. On postoperative histopathological evaluation, the tumor surprisingly displayed uniform clear-cell differentiation. No nuclear features suggestive of papillary thyroid carcinoma were observed, and differential diagnoses such as medullary thyroid carcinoma, metastatic renal cell, and parathyroid carcinoma were ruled out. The histological investigation revealed intracapsular collections of tumor cells displaying a debatable relation to the surrounding capsule and blood vessels, and the final diagnosis was a follicular tumor of uncertain malignant potential (FT-UMP) as defined by the WHO 2017 classification. As subsets of FT-UMPs with TERT promoter mutations do recur as advanced malignant tumors, a sequencing analysis was undertaken but could not identify TERT promoter mutations at position C228 or C250. To our knowledge, no previous literature has described a clear cell phenotype in an FT-UMP. We therefore advocate that endocrine pathologists should be aware of this entity in addition to ccFTAs and ccFTCs.

Cancers ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 1443 ◽  
Author(s):  
Hysek ◽  
Paulsson ◽  
Jatta ◽  
Shabo ◽  
Stenman ◽  
...  

Mutations of the Telomerase reverse transcriptase (TERT) gene promoter are recurrently found in follicular thyroid carcinoma (FTC) and follicular tumors of uncertain malignant potential (FT-UMP), but nearly never in follicular thyroid adenoma (FTA). We, therefore, believe these mutations could signify malignant potential. At our department, postoperative TERT promoter mutational testing of FT-UMPs was implemented in 2014, with a positive mutation screening leading to vigilant follow-up and sometimes adjuvant treatment. To date, we screened 51 FT-UMPs and compared outcomes to 40 minimally invasive FTCs (miFTCs) with known TERT genotypes. Eight FT-UMPs (16%) displayed TERT promoter mutations, of which four cases underwent a completion lobectomy at the discretion of the patient, and a single patient also opted in for radioiodine (RAI) treatment. Three mutation-positive patients developed distant metastases, registered in one patient receiving a completion lobectomy and in two patients with no additional treatment. Three out of four patients who received additional surgery, including the RAI-treated patient, are still without metastatic disease. We conclude that FT-UMPs with TERT promoter mutations harbor malignant potential and exhibit at least similar recurrence rates to TERT-promoter-mutated miFTCs. Mutational screening should constitute a cornerstone analysis in the histopathological work-up of FT-UMPs.


2018 ◽  
Vol 29 (4) ◽  
pp. 380-383 ◽  
Author(s):  
Johan O. Paulsson ◽  
Anton Olander ◽  
Felix Haglund ◽  
Jan Zedenius ◽  
C. Christofer Juhlin

Oncotarget ◽  
2016 ◽  
Vol 7 (14) ◽  
pp. 18346-18355 ◽  
Author(s):  
Langping Jin ◽  
Endong Chen ◽  
Siyang Dong ◽  
Yefeng Cai ◽  
Xiangjian Zhang ◽  
...  

2016 ◽  
Vol 31 (1) ◽  
pp. 100 ◽  
Author(s):  
Min Ji Jeon ◽  
Won Gu Kim ◽  
Soyoung Sim ◽  
Seonhee Lim ◽  
Hyemi Kwon ◽  
...  

PLoS ONE ◽  
2016 ◽  
Vol 11 (4) ◽  
pp. e0153319 ◽  
Author(s):  
Jian Sun ◽  
Jing Zhang ◽  
Junliang Lu ◽  
Jie Gao ◽  
Xinyu Ren ◽  
...  

2015 ◽  
Vol 51 ◽  
pp. S583
Author(s):  
K. Wang ◽  
S. Ganesan ◽  
A. Johnson ◽  
J.P. Sharman ◽  
A. Chachoua ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document